Medtronic PLC $MDT Stake Lifted by Aberdeen Group plc

Aberdeen Group plc raised its stake in Medtronic PLC (NYSE:MDT) by 1.1% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 2,576,475 shares of the medical technology company’s stock after buying an additional 28,932 shares during the quarter. Aberdeen Group plc owned approximately 0.20% of Medtronic worth $247,496,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Worth Financial Advisory Group LLC boosted its stake in Medtronic by 4.4% during the 4th quarter. Worth Financial Advisory Group LLC now owns 8,180 shares of the medical technology company’s stock valued at $786,000 after purchasing an additional 343 shares during the period. Dorato Capital Management acquired a new stake in shares of Medtronic in the fourth quarter valued at approximately $66,000. HF Advisory Group LLC raised its holdings in shares of Medtronic by 290.2% during the fourth quarter. HF Advisory Group LLC now owns 59,447 shares of the medical technology company’s stock valued at $5,710,000 after buying an additional 44,212 shares during the last quarter. Ellsworth Advisors LLC raised its holdings in shares of Medtronic by 5.7% during the fourth quarter. Ellsworth Advisors LLC now owns 62,008 shares of the medical technology company’s stock valued at $6,139,000 after buying an additional 3,350 shares during the last quarter. Finally, Compagnie Lombard Odier SCmA boosted its position in shares of Medtronic by 10.7% during the fourth quarter. Compagnie Lombard Odier SCmA now owns 110,850 shares of the medical technology company’s stock worth $10,648,000 after buying an additional 10,720 shares during the period. Institutional investors and hedge funds own 82.06% of the company’s stock.

Insider Activity

In other news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the sale, the executive vice president owned 32,768 shares in the company, valued at approximately $3,201,761.28. This represents a 61.58% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.26% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Citigroup started coverage on Medtronic in a report on Tuesday, February 3rd. They issued a “buy” rating and a $117.00 price objective for the company. Leerink Partners reiterated an “outperform” rating and set a $119.00 price target on shares of Medtronic in a research report on Tuesday, March 10th. Robert W. Baird decreased their price target on Medtronic from $103.00 to $100.00 and set a “neutral” rating for the company in a research note on Wednesday, February 18th. Daiwa Securities Group lowered their price target on Medtronic from $117.00 to $115.00 and set a “buy” rating on the stock in a report on Friday, February 27th. Finally, Piper Sandler reduced their price objective on shares of Medtronic from $105.00 to $91.00 and set a “neutral” rating for the company in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $109.85.

Medtronic Stock Performance

Shares of NYSE MDT opened at $86.61 on Friday. The stock has a fifty day moving average price of $94.76 and a two-hundred day moving average price of $96.27. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. The firm has a market cap of $111.19 billion, a P/E ratio of 24.12, a PEG ratio of 2.22 and a beta of 0.75. Medtronic PLC has a 1 year low of $79.55 and a 1 year high of $106.33.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The company had revenue of $9.02 billion for the quarter, compared to the consensus estimate of $8.89 billion. During the same quarter in the previous year, the business earned $1.38 EPS. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Research analysts forecast that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 17th. Shareholders of record on Friday, March 27th will be given a $0.71 dividend. The ex-dividend date is Friday, March 27th. This represents a $2.84 annualized dividend and a yield of 3.3%. Medtronic’s payout ratio is 79.11%.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).